FINERENONE IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: A FIDELITY ANALYSIS

https://storage.unitedwebnetwork.com/files/1099/f5f72b4002f759ef0fc56a983325a7ea.pdf

Yu An mealie328@126.com National Clinical Research Center of Kidney Diseases Nanjing University School of Medicine Nanjing

Hongguang Zheng phd528@vip.163.com General Hospital of Northern Theater Command Shenyang

Weiping Lu hyhalwp@sina.com The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University Nanjing

Zhaohui Mo mzh1964@126.com The Third Xiangya Hospital of Central South University Changsha

Xu Xudong xxdmzx@sina.com Fudan University Minhang Hospital Shanghai

Lu Yibing Luyibing2004@126.com The Second Affiliated Hospital of Nanjing Medical University Nanjing

Chaoqing Wu 13878862195@163.com The People’s Hospital of Guangxi Zhuang Autonomous Region Nanning

Jingyuan Xie nephroxie@163.com Shanghai Jiao Tong University School of Medicine Ruijin Hospital Shanghai

Nanwei Tong tongnw@scu.edu.cn Sichuan University West China Hospital Chengdu

Fang Liu liufangfh@163.com Sichuan University West China Hospital Chengdu

Qinkai Chen timmyclz@163.com The First Affiliated Hospital of Nanchang University Nanchang

Meike Brinker meike.brinker@bayer.com Bayer AG Cardiology and Nephrology Clinical Development Wuppertal

Dalong Zhu zhudalong@nju.edu.cn Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital Nanjing

Zhihong Liu liuzhihong@nju.edu.cn Nanjing University School of Medicine National Clinical Research Center of Kidney Diseases, Jinling Hospital Nanjing